What did @holisticglpgirly actually say?
The creator describes a nightly peptide stack that includes GHK-Cu (copper tripeptide), which she calls "the ultimate beauty peptide," and a mix she refers to as "Epimorlin and CJC." She credits GHK-Cu with supporting hair, skin, nails, and collagen while taking a GLP-1 medication. She says the second peptide helps with "fat burning, muscle growth" and that it makes her "sleep like a freaking baby." She also recommends a specific vendor she personally vetted and frames the whole routine as anti-aging and longevity support.
To be clear about terminology: "Epimorlin" is not a widely recognized compound name in the literature. The most likely intended peptide is ipamorelin, a selective growth hormone secretagogue, often paired with CJC-1295. That combination is what this fact-check will address, because that is the stack most consistent with her described effects.
Does the science back this up?
Partly, but the gap between preclinical data and what she implies is significant. GHK-Cu has real published research behind it. Ipamorelin/CJC-1295 has plausible mechanisms for sleep and body composition. The fat-burning framing, though, overstates what the evidence actually shows.
GHK-Cu has been studied for wound healing, skin remodeling, and hair follicle stimulation. A 2019 review by Pickart and Margolina in Biomolecules summarized decades of research showing GHK-Cu promotes collagen synthesis and activates hair follicle cycling in vitro and in some animal models. Human clinical data is thinner, but a 2007 study by Leyden et al. in the Journal of Cosmetic Dermatology found topical GHK-Cu improved skin density and thickness. Most of that research, it should be noted, involves topical formulations, not injectable peptides.
For ipamorelin/CJC-1295, the sleep connection is biologically reasonable. Growth hormone (GH) secretion is highest during slow-wave sleep, and GH secretagogues can amplify that pulse. A 1997 study by Frieboes et al. in Journal of Psychiatric Research showed GHRH administration increased slow-wave sleep in healthy men. Ipamorelin mimics a similar pathway. The "fat burning" claim is a stretch. GH does influence lipolysis, but clinical trials in adults haven't shown the kind of body composition transformation the language implies without diet and exercise context.
What did they get wrong (or right)?
She gets credit for pairing GHK-Cu with a GLP-1 medication context. GLP-1 agonists are associated with hair shedding in some users, likely through rapid weight loss triggering telogen effluvium. GHK-Cu's potential role in supporting follicle cycling is a reasonable harm-reduction consideration, though not yet proven in this specific scenario.
She gets it wrong on the fat-burning framing. Calling ipamorelin/CJC "for fat burning" implies a direct weight-loss effect. The actual mechanism is indirect: GH influences metabolic signaling, but the clinical evidence for meaningful fat loss from GH secretagogues in non-deficient adults is weak. A 2010 review by Svensson et al. in Growth Hormone and IGF Research found modest changes in body composition with GH treatment but noted effects were largely dependent on baseline GH status.
The vendor endorsement is also a problem. She says the company "tests every single vial," but she provides no information about what testing is performed, by which accredited lab, or what certificates of analysis look like. That framing functions as an advertisement dressed as a safety tip. Peptides sold outside regulated pharmacy channels are not FDA-approved and carry real quality control risks, including contamination and inaccurate dosing.
What should you actually know?
Injectable peptides like ipamorelin, CJC-1295, and GHK-Cu are not FDA-approved drugs for any of the conditions discussed in this video. That does not make them automatically dangerous, but it does mean there are no standardized manufacturing requirements, no required clinical trials for the specific uses promoted, and no regulatory body verifying what is in any given vial from a private vendor.
GHK-Cu as an injectable has far less human safety data than its topical counterpart. Ipamorelin and CJC-1295 have been studied in clinical trials, primarily for GH deficiency, not healthy adults seeking body composition or sleep benefits. Using them off-label without physician supervision means no one is monitoring for elevated IGF-1, potential effects on glucose metabolism, or interactions with other medications including GLP-1 agonists.
If you are on a GLP-1 medication and experiencing hair loss, that is a conversation to have with a licensed provider, not a TikTok peptide stack to self-assemble. Any peptide protocol involving injectable compounds should involve a prescription, a compounding pharmacy regulated under USP standards, and clinical monitoring. A social media vendor vouched for by an influencer does not meet that bar.